RecruitingNCT04978948

Study of STIM1 Membrane Expression

Study of STIM1 Membrane Expression During Autoimmune Diseases


Sponsor

University Hospital, Brest

Enrollment

670 participants

Start Date

May 11, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

The aim of this study is to determine the expression of STIM1 in the plasma membrane of lymphocytes from patients suffering from different autoimmune diseases in order to identify new pathologies of interest presenting an over-expression of STIM1PM. This would allow to initiate, following this study, research and development programs on the use of anti-STIM1 antibodies in these identified autoimmune diseases of interest.


Eligibility

Min Age: 18 YearsMax Age: 99 Years

Inclusion Criteria1

  • Diagnosis of one of the autoimmune diseases

Exclusion Criteria1

  • Treatment with rituximab in the previous 12 months

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(4)

CHRU de Brest - Service de rhumatologie

Brest, Brest, France

Centre Hospitalier des Pays de Morlaix

Morlaix, Brittany Region, France

Centre Hospitalier de Quimper

Quimper, Brittany Region, France

CHU de Martinique

Fort-de-France, Martinique, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04978948


Related Trials